Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech's patent related to use of laquinimod as
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active
FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma Active Biotech.
The number of shares and votes in Active Biotech has changed as a result of allotment of performance shares under the company's incentive program for the company's employees (Plan 2020/2024). Today